<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref064">
 <label>64</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Lohmeyer</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Nerreter</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Dotterweich</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Einsele</surname>
   <given-names>H</given-names>
  </name>, 
  <name>
   <surname>Seggewiss-Bernhardt</surname>
   <given-names>R</given-names>
  </name>. 
  <article-title>Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner</article-title>. 
  <source>Clin Exp Immunol</source>. 
  <year>2018</year>;
  <volume>193</volume>(
  <issue>1</issue>):
  <fpage>64</fpage>â€“
  <lpage>72</lpage>. Epub 2018/03/25. 
  <pub-id pub-id-type="doi">10.1111/cei.13128</pub-id>
  <?supplied-pmid 29573266?>
  <pub-id pub-id-type="pmid">29573266</pub-id>
 </mixed-citation>
</ref>
